Mohit Patel -- Disruptive Diner: Nano Possibilities

•

1 like•752 views

Presentation from 10/15/13 on innovative startup producing cost effective nano particle kits to get large amounts of DNA into cells without damaging them. Genetix Fusion LLC founder Mohit Patel explains how nanotech makes this possible and the enormous time and cost problems they're able to address. Join OpenlyDisruptive.org for live access to more disruptive innovation events.

Technology Business

The next generation of
Gene Delivery

Mohit B. Patel

What is Nano?
Macro

Nano

Millionth
(10-‐6)

Human
Being

6
feet
tall

Micro

Billionth
(10-‐9)

Red
Blood
Cell

8
micrometer

DNA

2nm
wide

Nanotechnology
Energy

Nanomedicine

Nanosensors

Broad
range
of
applica<ons

Genetic Material

Tissue

Gene

Cell

Body

Chromosome

DNA

Genetic Disorders
Illness
caused
by
an
abnormality
in
an
individuals

DNA/gene.

Gene Delivery

Gene
Delivery

Gene
Expression

Research applications: Genetic disorders, gene therapy, protein
production, functional genomics, disease diagnostics and
agriculture crop enhancement

Gene Delivery

Transfection: Laboratory procedure to delivery foreign DNA
into host cells.

Physical methods
Electropora5on

Gene
gun

Microinjec5on

Advantage:
Can
transfer
large
DNA
molecules

Disadvantage:
Highly
cytotoxic
and
expensive

Biological methods

Advantage:
Stable
transfec<on

Disadvantage:
High
risk
and
<me
consuming

Chemical methods
Calcium
phosphate

Lipids

Nanotubes

Advantage:
Good
eﬃciency

Disadvantage:
Cytotoxic
and
limited
gene<c
informa<on

Limitations of Existing Products
•  Toxic to cells

$6000 and
30 days / year for
each scientist

•  Limited size
(kilobases, kb)
•  Poor efficiency
•  Time consuming
•  Inconsistent results
•  Costly
11

“Transfection market
clamors for silver
bullet.”

Solution: Janus Transfection Kit™
Janus Transfection Kit™ utilizes a new class of chemical
reagent for DNA transformation and transfection.
New Class = non-lipid, non-viral and
non-dendrimer based transfection reagent

Janus Transfection Kit™
Proprietary
Platform Technology
12

Janus Transfection
Reagent™

STEP 1
STEP 2
STEP 3

Efficiency: Janus Transfection Kit™
60
50
40
30
20
10
0

Yeast
Colony forming units

Colony forming units

Bacteria

Janus Transfection Promega's Product
Reagent™

600
500
400
300
200
100
0

Mammalian cells
Number of cells
transfomed

0.00%
Janus Transfection
Reagent™

Control

Standard Reagent

Plants

100.00%

50.00%

Janus Transfection
Reagent™

60
50
40
30
20
10
0
Janus Transfection
Reagent™

Control

Competitive Advantages
Janus Transfection Kit™ will save each researcher
an estimated 65% of cost and 50% of time.
Company
In-House
Invitrogen
Sigma Aldrich
Promega
Qiagen

DNA Size
<7kb
~9-12kb
~11kb
~7-10kb
~9-12kb

Toxicity
High
High
Low
Low
Medium

Genetix
Fusion

>20kb

None Very High
15

Cell Versatility
Low
High
Medium
Medium
Medium

Price
$ 413
$ 485
$ 333
$ 440
$ 288

$ 350

Solution: Janus Transfection Kit™
Enables use of larger DNA
High efficiency
Non-mutagenic and non-cytotoxic

Broad range of applications

Transfection Market
$13.4 Billion market
DNA and RNA delivery
$346 Million
Genetix Fusion accessible market
Academia 68% ($235 M)
Pre-packaged kits 75% ($259 M)

Critical Milestones
Launch first
product

Genetix Fusion
founded
Alpha
prototype
tested

Initial funding
raised

May
2012

PCT
application

Provisional
patent
Beta prototype

1% Market
(~5500 units)

Controlled
market release

January
2018

January
2014
Establish
operations

Today

January
2015

Strategic
distribution
partner

4% Market
(~28000 units)

Now Seeking
1.  Academic researchers for beta
testing
2.  Collaborative opportunities
3.  Distribution partner
4.  Seed stage investment

REDEFINING TRANSFECTION
Contact us:
mohitpatel87@gmail.com
www.genetixfusion.com
(314) 516-4607

Watch the presentation of this webinar here: https://bit.ly/33WUiqE Ensuring the safety and quality of your lentiviral vector is of the utmost importance. Attend this webinar to learn about testing strategies to monitor replication competent lentivirus. You will also hear about recent changes in regulatory guidance with regards to sample types and volumes tested. The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production. This webinar reviews the strategies for monitoring replication competent lentiviruses. We describe current methods and address: Sample types, testing volumes, and expected results. In this webinar, you will learn about: • The latest FDA regulatory guidelines on replication competent lentivirus (RCL) testing • Methods used to monitor RCL • Considerations on sample type and volume requirements

Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing

MilliporeSigma

Emerging viruses represent a constant challenge to biopharmaceutical manufacturers, and therefore formal risk assessments and informed programs of safety testing are necessary to assure safety. Emerging viruses such as the Zika virus have the potential to contaminate raw materials of human origin, Schmallenberg virus is a contaminant of bovine serum, and the long-known, but often ignored, Hepatitis E virus represents further challenges to the safety of raw materials. Results of in vitro culture and molecular testing strategies of raw materials for viruses with diverse characteristics will be presented, and holistic approaches to mitigate the risk of novel viruses to the safety of raw materials will be outlined. In this webinar, you will learn: -The identity of emerging viruses and potential impact on the safety of raw materials and final products -Testing strategies for specific viruses -Holistic approaches to mitigate the risk of novel viruses in raw materials

Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines

Merck Life Sciences

To date, manufacturing of lentivirus (LV) vectors for gene therapy commonly relies on transient transfection of adherent HEK293 cells. This method is costly, time-consuming, difficult to scale-up and poorly reproducible, rendering large-scale applicability to fulfill increasing demand of LV in clinical pipelines cumbersome. The use of suspension-adapted transient producer cell lines for LV production has overcome some of these challenges. Furthermore, successful creation of stable producer cell lines would allow creation of master and working cell banks easily amenable to commercial production. The ideal producer cell lines should demonstrate stability in growth and gene expression, and be easily adaptable to chemically defined culture conditions and optimized for high-titer virus production. The availability of more robust producer cell lines thus represents an important scalable first step towards manufacturing processes that are conducive to large-scale production. Ultimately, these producer cell lines must be screened to satisfy various biosafety and regulatory implications. In this webinar, you will learn: • Process development for transient and stable producer cell lines • Screening of cellular gene targets via CRISPR to improve LV production from producer cell lines • cGMP and Regulatory readiness: Cell line characterization and release testing through BioReliance® global service offering

Biosafety Testing Solutions for Cell & Gene Therapy

Merck Life Sciences

Abstract: Cell and gene therapies, well recognized as the drug revolution for this decade, are booming in Asian countries. Several cell and gene therapeutic products launched successfully in Europe and the US. The commercialization of these therapies is a hot topic, while ensuring product safety, especially quality for the new modalities, raises challenges within the industry. As a globally leading biosafety testing provider, Merck is committed to optimizing and advancing innovation and development of biosafety testing. As your reliable partner in CMC consideration, our comprehensive solutions for cell and gene therapy biosafety testing enable regulatory compliance. This presentation will cover rationale and methodologies for cell and gene therapy product testing from Merck’s BioReliance® testing portfolio, as well as provide an overview of our testing capabilities and services.

Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3pCCjPF Ensure your Adeno-Associated Virus (AAV) is safe throughout its entire drug development journey. Learn methods that will help you speed to clinic, potentially treating diseases sooner and with greater effectiveness. The potential of gene therapies to cure previously untreatable diseases has spurred the development of novel drugs, including those based on Adeno-Associated Virus (AAV). As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy. In this webinar, we will present a range of orthogonal methods to understand and define the CQAs of AAV products. These include assays for the confirmation of capsid protein identity and quantity, as well as the characterization of important product-related impurities, such as aggregates. Together these methods represent a comprehensive analytical testing package to support the characterization and lot release of AAV products. In this webinar, you will learn: • How to identify and monitor the critical quality attributes (CQAs) of your AAV therapy • What assays to utilize to confirm capsid protein identity and quantity • Why you need look to product characterization to identify and remove important product-related impurities

From Sample to Result – Workflow Solutions for Genotyping and Pathogen Detection

QIAGEN

PCR multiplexing and HRM (High Resolution Melting) have been proven to be powerful approaches for genotyping and pathogen detection. In this slidedeck, we discuss several challenges in these workflows that include pathogen extraction, isolation and analysis. We also present a streamlined workflow for bovine disease detection and monitoring using multiplex assays from soil and bovine stool samples, while also using HRM analysis as a potential tool for microbiome signature identification and monitoring. An optimized and robust assay system using QIAGEN’s QuantiFast Multiplex PCR Kit, HRM genotyping PCR kit and QuantiNova kit is introduced in the context of applications. Learn how you can optimize your workflow and get accurate results for your genotyping and pathogen detection research in this slidedeck.

Development of Production and Purification Platformform for Influenza Vaccine

Dr. Priyabrata Pattnaik

Watch the presentation of this webinar here: https://bit.ly/3icKkbZ Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays. Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors. This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50. In this webinar, you will learn: • Critical biosafety considerations for AAV vectors based on the latest regulatory guidance • How replication competent AAV testing fits into your bulk and final release testing package • The benefits of routine and platform assays over custom assay development Presented by: Steven McDade, Senior Technical Specialist, Field Technology Management Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services

An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...

MilliporeSigma

Come learn more about our integrated approach to ensure viral vector and gene therapy commercial readiness. We will discuss topics relating to process development for viral vector manufacturing, biosafety testing and commercial readiness. Significant progress has been made for the use of viral vectors for gene therapy. Promising clinical trial results as well as recent FDA approval for CAR-T cell therapy to treat certain children and young adults with B-cell lymphoblastic leukemia have signaled advancements in the field. This marks a historic action, providing opportunities for new viral vector technologies to transform medicine and the way patients are treated and even cured. The need for process development for viral vector manufacturing to improve yield to meet patient demand, biosafety testing for product characterization, potency and safety and commercial readiness to accelerate therapy to-market are critically important. Here, we emphasis an integrated approach that allows our customers solutions to ensure viral vector and gene therapy commercial readiness to meet the growing market need. In this webinar, you will learn: ● Process development advances for production scale-up of viral vectors for gene therapy ● Methods specific for viral gene therapy product characterization, purity, potency, safety and release testing ● Commercial readiness through our US and UK Centers of Excellence for viral product manufacturing

Anti Virus Biomolecular Discovery - Creative Biolabs

Creative-Biolabs

Creative Biolabs is the leading custom service provider in antibody development and engineering. Our scientists bring state-of-the-art technology to support functional antibody and peptide discovery services against viruses. Here, we will introduce the virus and its pathogenic mechanism in detail. At the same time, you will learn how to obtain functional anti-virus antibodies and peptides through our technology platform.

Presentation Sirion Web V7 Spoken

biofrost

Virus Safety in Vaccine Production

Dr. Priyabrata Pattnaik

See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis

MilliporeSigma

Watch this webinar here: https://bit.ly/31ZZM3n Join this webinar for key insights on using the SV-AUC assay for empty/full analysis of your AAV viral vector. We’ll cover the technical requirements for this assay, data interpretation, and finally how this assay fits into the larger picture of AAV characterization. Recombinant adeno-associated viruses (AAV) are widely used as gene transfer vectors. However, AAV production generates mixed populations of viral capsids containing either complete viral vector genome (full capsids); partially filled, and those lacking the viral genome (empty capsids). Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) offers a robust, accurate, and consistent method for characterizing empty/full AAV capsid composition. In this webinar we will review the key technical requirements for performing an AUC assay as well as analysis and data interpretation of the results generated. In this webinar, you will learn: • Regulatory expectations for empty/full analysis • Key technical requirements for running an AUC assay and how to interpret the data from the results generated • How the AUC assay fits into the larger picture of AAV characterization

Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3jmLYHu State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed. The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform. In this webinar, you will learn: • Benefits of platform technologies in vaccine development • Key considerations when deciding between platforms • Vaccine pipeline analysis and selected case studies Presented by: David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy

Does your cell line have a secret? Avoid surprises with characterization

Merck Life Sciences

Watch the recording of this webinar here: https://bit.ly/2Y05bV4 The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks. Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed. In this webinar, you will learn: • The types of tests that are needed to fully characterize your cell banks • The best tests to use for your particular cell line • Reasons why a viral contaminant may be missed

BILS 2015 Genethon M. Hebben

GBX Events

Developing a single use adenovirus-vectored vaccine process through public-pr...

Merck Life Sciences

This work highlights the importance of collaborations to accelerate vaccine process development and manufacturing under the constant pressure of emerging diseases and the growing need of global immunizations. We are collaborating with the Jenner Institute of the University of Oxford to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as vector for vaccines such as Rabies and emerging threats like Zika and Ebola. This webinar will describe the transition from a labor and time intensive process development to one utilizing a maximum of disposable technologies such as single use bioreactors and filtration technologies, using the rabies vaccine as a first candidate. We will highlight the challenges and their corresponding solutions that in the end created a template that can be used for different types of adenoviral vectors-based vaccines manufacturing. In this webinar, you will learn: - The challenges of creating a rapid and scalable process for Adenovirus vector manufacturing. - The solutions that overcame those challenges. - How public-private collaborations can accelerate vaccine process development.

Importance of microbes in genetic engineering

Uththara Rathnapriya

Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3b3Jc77 Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure the robust process design, intensification and scalability that meets your evolving manufacturing needs? What benefits can a templated process bring to your commercial success? As gene therapy progresses toward broader clinical and commercial success, the industry is shifting from treating rare conditions to those of larger populations. This requires scalable solutions for process intensification. In this webinar, we’ll discuss scale-up development for a common viral vector in gene therapy, lentivirus, using the VirusExpress™ Lentiviral Production Platform in Mobius® single-use bioreactors. We will highlight critical considerations when moving from bench-scale to clinical scale process design with manufacturability in mind to ensure commercial readiness. Finally, we’ll review the significant benefits of implementing a templated manufacturing process. In this webinar you will learn: • Scale-up development of a suspension-based lentivirus production process • Designing a process that is manufacturing-friendly and supports commercialization • The benefits of having a templated manufacturing process

Turning up the Compen-DIAL: Rapid Test Methods for Cell & Gene Therapies

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3aeCPNB Find out how we turn up the dial on quality control testing for cell and gene therapies through rapid methods for sterility, mycoplasma, and replication competent virus. We will review the current regulatory expectations as well as the benefits and limitations that come with each method. Two of the biggest challenges with applying traditional quality control (QC) test methods to cell and gene therapies, is time to results, due to short shelf-life, and availability of sufficient sample, due to small production volumes. So how can these challenges be overcome while still meeting regulatory expectations? In this webinar we will discuss and review suitable methods for rapid testing of short-life cell and gene therapies that may also help conserve limited production material. We will look at benefits, limitations, and regulatory expectations for various QC needs including current and future rapid methods for sterility, mycoplasma and replication competent virus. In this webinar, you will learn: • Why the shelf life of a cell or gene therapy product may impact your QC testing strategy • Current regulatory expectations surrounding rapid methods for sterility, mycoplasma and replication competent virus • Potential impacts of pursuing a non-optimal QC testing strategy

Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3ryE5ST Optimize your mesenchymal stem cell growth. Join our webinar to learn more about our GMP-compliant xeno free media formulation that supports high performance expansions and compatibility with scalable xeno free manufacturing conditions. Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high quality raw materials are essential for therapeutic access. The GMP-compliant Stemline® XF MSC Medium and cocktail promotes expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures. In this webinar, you will: • Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells • Discover ways to derive MSC's from Bone Marrow in Xeno Free conditions from static to microcarrier-based suspension culture platforms. • Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks Presented by: Kathleen Ongena, Ph.D., Head of Customer Applications and Mark Ventresco, Cell Therapy Product Manager

Linkedin Gen Scripthowardhuang

Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...

QIAGEN

Liquid biopsies enable us to monitor the evolution of genetic aberrations in primary tumors as they shed the tumor cells into the circulation. The limitation is the ability to detect these low frequency genetic aberrations in a consistent manner to understand short- and long-term implications and how this information will be used in the clinic. This slidedeck will cover the challenges and solutions associated with multiple steps as one starts with liquid biopsy and move towards finding a new biomarker.

PPT MOLECULAR DIG gram +ve bacteria.....

Dr. Ajit Surya Singh

Strain improvement technique

rekha sharma

Chloroplast genome engineering

Seyed Javad Davarpanah

Microbial strain selection..

Mujahid Iqbal

strain improvement to increase yeild of selected molecules.pptx

berciyalgolda1

What's hot

Ingenza BILS 2016

GBX Events

Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...

Merck Life Sciences

An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...

MilliporeSigma

Anti Virus Biomolecular Discovery - Creative Biolabs

Creative-Biolabs

Presentation Sirion Web V7 Spoken

biofrost

Virus Safety in Vaccine Production

Dr. Priyabrata Pattnaik

See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis

MilliporeSigma

Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing

Merck Life Sciences

Does your cell line have a secret? Avoid surprises with characterization

Merck Life Sciences

BILS 2015 Genethon M. Hebben

GBX Events

Developing a single use adenovirus-vectored vaccine process through public-pr...

Merck Life Sciences

Importance of microbes in genetic engineering

Uththara Rathnapriya

Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...

Merck Life Sciences

Turning up the Compen-DIAL: Rapid Test Methods for Cell & Gene Therapies

Merck Life Sciences

Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...

Merck Life Sciences

Linkedin Gen Scripthowardhuang

What's hot (16)

Ingenza BILS 2016

Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...

An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...

Anti Virus Biomolecular Discovery - Creative Biolabs

Presentation Sirion Web V7 Spoken

Virus Safety in Vaccine Production

See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis

Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing

Does your cell line have a secret? Avoid surprises with characterization

BILS 2015 Genethon M. Hebben

Developing a single use adenovirus-vectored vaccine process through public-pr...

Importance of microbes in genetic engineering

Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...

Turning up the Compen-DIAL: Rapid Test Methods for Cell & Gene Therapies

Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...

Linkedin Gen Script

Similar to Mohit Patel -- Disruptive Diner: Nano Possibilities

Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...

QIAGEN

PPT MOLECULAR DIG gram +ve bacteria.....

Dr. Ajit Surya Singh

Strain improvement technique

rekha sharma

Chloroplast genome engineering

Seyed Javad Davarpanah

Microbial strain selection..

Mujahid Iqbal

strain improvement to increase yeild of selected molecules.pptx

berciyalgolda1

Axt microarrays

Heidi Barrier

Overcoming challenges of host cell DNA removal in vaccine manufacturing

Dr. Priyabrata Pattnaik

Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...

QIAGEN

Setting up for successful lot release testing by Edmund Ang

MilliporeSigma

Is your lot release testing strategy ready for global commercialization? In this webinar, you will learn: • CMC testing requirements with CHO production platform for global commercialization • Lot release testing of product intermediates and final product • Product-specific qualification study • Alternative rapid testing methods to advance lot release testing CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines. In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.

Setting up for successful lot release testing by Edmund Ang

Merck Life Sciences

Vectors Used for Gene Cloning in Plants

Arunodaya Maji

Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...

QIAGEN

The research community has begun correlating the makeup of individual microbiomes with disorders and diseases such as autism, atherosclerosis, obesity and cancer. To accomplish this, researchers must first identify and characterize these microbial communities. This slidedeck will begin with a general introduction of metagenomics and an overview of experimental strategies. Following this, a comprehensive microbiome assay pipeline will be introduced. We conclude with application-based examples that demonstrate how to identify and characterize microbiome profiles.

Addressing the Challenge of Scalability in Viral Vectors

MilliporeSigma

Watch this webinar here: https://bit.ly/3jlcEXH Addressing the Challenge of Scalability in Viral Vectors To meet the ever-increasing demands for cell and gene therapies, there is a need to shift away from expensive, labor-intensive cell culture and scale up systems. But this goal cannot be met without a robust production strategy based on clinical indication, population size and dosing requirements. Early viral vector process development for cell and gene therapies is critical to assure a production strategy that supports commercial needs based on clinical indication, population size and dosing requirements. Most production processes today rely on labor-intensive and expensive adherent cell culture systems and scale out approaches. This webinar will highlight the importance of a scalable process that supports clinical through commercial needs. We will introduce a suspension-based process we have developed, including a HEK 293T cell line, chemically defined media, and optimized process conditions that results in higher yield, easier scalability, and lower production costs. In this webinar, you will learn: • Why suspension cell based processes are easier, faster, and more economical than adherent cell growth cultures • Use of chemically defined medium for improved cellular growth, viral productivity, easier downstream purification and improved safety from adventitious agents • Unraveling the complexities of the HEK293 and 293T cell lines • The importance of planning for scalability and manufacturability from the earliest stages of process development • How a scalable templated process can reduce time needed to move from product development to commercialization

Addressing the Challenge of Scalability in Viral Vectors

Merck Life Sciences

Linkedin Gen Scripthowardhuang

Plasmid Manufacturing Service from GenScript ProBio

GenScript ProBio

GenScript ProBio offers the best Plasmid Manufacturing Service and employs a GMP-compliant plasmid production process that allows customers to replicate DNA used in experiments with minimal additional effort. By employing this process, Genscript can provide plasmids produced at the highest quality standards. For more information, visit our website. https://www.genscriptprobio.com/gct-proplasmid.html

Биоплазмоника - биочипы для экспресс-диагностики патологий организма и заболе...

Dmitriy Filippov

Диагностические устройства на основе эффекта гигантского комбинационного рассеяния света (SERS диагностика ) для анализа молекулярных маркеров патологий в организме (онкологические заболевания, диабет и т.д.). Высокоточное, быстрое определение уровней гликированных гемоглобинов (HbA1с) и альбуминов (ГлА) в сыворотке крови для диагностики метаболических нарушений в организме (сахарного диабета, почечной недостаточности, гипотиреоза). Возможно расширение области применения: ранняя диагностика онкологических заболеваний, предотвращение угрозы терроризма, распространения опасных и токсичных химических веществ, наркотических веществ, контроль качества сырья. SERS biochips for express analysis of molecular markers of different diaseses. Quick and presize measurement of HbA1с and albumins in blood serum for diagnosis of diabetes, renal disease, hypothyrosis and cancer.

Genetic Analysis Solutions for Plant Sciences

Thermo Fisher Scientific

This slide deck uses case studies and scientific publications to highlight how Life Technologies platforms and products are used in plant genetic analysis applications such as plant genome sequencing, SNP genotyping, marker assisted selection, GMO detection, plant genetic engineering, plant gene expression, and plant nucleic acid isolation. Life Technologies is committed to providing instruments, reagents, and technologies for Plant Sciences and Genomic Applications that will lead the way to remarkable agricultural discoveries—everything from improved crops that feed more people to sustainable biofuels that keep things moving.

Molecular QC: Using Reference Standards in NGS Pipelines

Candy Smellie

Since its inception, next-generation sequencing has found utility in a diverse set of industries, from biomarker discovery in pharma to ancestral identification in archeology. Across the board, NGS has the advantage of allowing us to answer questions that require a lot of data. Next-generation sequencing provides orders of magnitude more data than traditional Sanger sequencing as hundreds of “lanes” analyzed in parallel vs. hundreds of millions of “clusters” which allows for many samples to be multiplexed on a single-run. By starting with different genetic material and following specific experimental workflows, NGS can be applied to many applications. Here we focus on DNA resequencing applications, which implies the data generated will be compared to an existing reference sequence (such as the human genome). Specifically, we’ll focus on how we can analyze patient-derived material to identify onco-relevant mutations including single-nucleotide variants, insertions-deletions, copy number variants and translocations. We’ll also focus on how known reference standards have been shown to be vital in ensuring data generated from NGS assays is accurate and reproducible.

Similar to Mohit Patel -- Disruptive Diner: Nano Possibilities (20)

Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...

PPT MOLECULAR DIG gram +ve bacteria.....

Strain improvement technique

Chloroplast genome engineering

Microbial strain selection..

strain improvement to increase yeild of selected molecules.pptx

Axt microarrays

Overcoming challenges of host cell DNA removal in vaccine manufacturing

Targeted Single Cell Sequencing for Accurate Mutation Detection in Heterogene...

Setting up for successful lot release testing by Edmund Ang

Vectors Used for Gene Cloning in Plants

Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...

Addressing the Challenge of Scalability in Viral Vectors

Linkedin Gen Script

Plasmid Manufacturing Service from GenScript ProBio

Биоплазмоника - биочипы для экспресс-диагностики патологий организма и заболе...

Genetic Analysis Solutions for Plant Sciences

Molecular QC: Using Reference Standards in NGS Pipelines

More from Openly Disruptive

Eric Garland- Disruptive Diner: Local Investment, Local Wealth

Mohit Patel -- Disruptive Diner: Nano Possibilities

Recommended

Recommended

More Related Content

What's hot

What's hot (16)

Similar to Mohit Patel -- Disruptive Diner: Nano Possibilities

Similar to Mohit Patel -- Disruptive Diner: Nano Possibilities (20)

More from Openly Disruptive

More from Openly Disruptive (20)

Recently uploaded

Recently uploaded (20)

Mohit Patel -- Disruptive Diner: Nano Possibilities